Cervical dystonia …

Movement Disorders

Updated 03.06.2024
Released 09.06.1993
Expires For CME 03.06.2027

Cervical dystonia

Authors: Eric Steven Molho MD, Gary Volkell DO

See Contributor Disclosures

Editor: Robert Fekete MD

Cervical dystonia

In This Article

Quick Link

Introduction

Overview

Cervical dystonia is the most common focal dystonia, consisting of involuntary head and neck movements, which result in abnormal postures, tremor, and associated pain. The etiology remains unclear but appears heterogeneous, and this article discusses possible roles played by genetics, drug exposure, and trauma. Botulinum toxin injections have been a breakthrough in the treatment of this condition for the last 3 decades. Deep brain stimulation has been an alternative option for intractable cases.

Key points

	• Cervical dystonia is the most common form of focal dystonia.
	• Diagnosis is clinical and is based on history and examination.
	• An underlying cause is usually not identified, although secondary causes, especially drug-induced, should be excluded.
	• Treatment of choice is botulinum toxin injections and consideration of deep brain stimulation for severe cases not adequately responsive to injections.

Historical note and terminology

The features of cervical dystonia, consisting of abnormal head and neck posture with sustained or intermittent movements, have long been well known. Before the 18th century, several descriptions, sculptures, and paintings depict a possible abnormal position of the neck. Previously known as "spasmodic torticollis," cervical dystonia was defined as "an involuntary hyperkinesis involving the muscles of the neck primarily on one side" (53). In 1888, Charcot presented a case of a stockbroker who developed a clonic spasm in the sternocleidomastoid and trapezium after a catastrophic financial loss, which raised suspicion for psychogenic etiology (96). It was only in the 20th century that dystonia was separated as an organic etiology.

Clinical manifestations

Presentation and course

Patients with cervical dystonia have involuntary head and neck movements resulting in abnormal postures, spasmodic motions, or tremor. The most prominent feature is usually sustained rotational deviation of the head to one side.

Terms such as "laterocollis," "anterocollis," and "retrocollis" describe the direction of head movement tilted laterally, forwards, and backward, respectively. Anterocollis may be subdivided into conceptual anterocollis (when it involves exclusively the position of the cervical spine), anterocaput (when it affects exclusively the head position), and anterior or posterior sagittal shift (when it affects head and cervical spine positions) (52). Similarly, lateral tilt (laterocollis) can be distinguished from lateral shift of the head. A combination of these distortions of posture is usually present. Associated asymmetric hypertrophy of involved neck muscles is expected. Superimposed on the sustained abnormal posture may be fast components in the form of spastic jerks or head oscillation (tremor). Head oscillations are present in 28% to 68% of patients and can have a regular or irregular component (114). In fact, isolated head tremor can be a presenting feature. One longitudinal study followed 20 patients with an isolated head tremor and no other neurologic symptoms (51). After 5 years, 15 of those patients had developed dystonic posturing in the neck. The abnormal head and neck movements disappear when the patient is sleeping. There should be no contractures in most cases, but in patients with a prolonged history of cervical dystonia, there may be fixed deformities in the neck.

Patients may describe actions that improve the symptoms of cervical dystonia. This phenomenon, previously known as a “sensory trick” or “geste antagoniste,” has been renamed “alleviating maneuver” (101; 18). Alleviating maneuvers are helpful in establishing the diagnosis of cervical dystonia. In a study involving 154 subjects with cervical dystonia, 138 (89.6%) reported an alleviating maneuver (102). There was marked improvement of cervical dystonia in 39.8% of subjects and partial improvement in 43.4%. The most common alleviating maneuver was a light touch to the lower face or neck. Other alleviating maneuvers that have been described include resting the occiput against a wall, abducting the ipsilateral shoulder, placing objects on the head, or placing a hand above the head. The pathophysiological mechanisms of alleviating maneuvers are not well understood, but using paired-pulse transcranial magnetic stimulation in patients with cervical dystonia, these maneuvers were thought to improve dystonia through an inhibitory effect on motor cortex excitability (04).

Cervical dystonia and sensory trick

A 24-year-old man shows cervical dystonia that improves with sensory tricks. (Contributed by Dr. Ravindra Kumar Garg.)

Neck pain is a common feature of cervical dystonia. This and many other features of cervical dystonia were explored in the multicenter study, CD-PROBE, involving 1046 patients with cervical dystonia assessed after three consecutive treatments with botulinum toxin (64). In this study, neck pain was reported in over 95% of participants, and the rate of moderate to severe pain was 70.7% (24). In one multicenter, cross-sectional study, substance abuse was found in 11% of patients with cervical dystonia (85). Risk factors identified were younger age, male gender, and comorbid mood disorder.

Patients with cervical dystonia have been found to have an increased risk of secondary degenerative changes of the upper cervical spine, particularly C2/C3 and C3/4 on the side ipsilateral to the head tilt (27). Patients with degenerative changes had more restriction in head mobility and longer time without adequate treatment. Cervical arthritis can contribute to pain, limitation of head movement, and poor response to botulinum toxin and surgical therapy.

Headache attributed to craniocervical dystonia is included in the classification of the International Headache Society as a secondary headache (12). The pain is in the location of the muscles affected by the dystonia, and it follows a temporal progression with the cervical dystonia. However, a study that evaluated the frequency of headache in patients with and without cervical dystonia showed that the frequency of headache in both groups was similar (around 50%), and the most common headache type was migraine (06).

Swallowing function may be abnormal even before treatment, especially in patients with extreme retrocollis. In a study of 43 patients, over 50% of patients had objective findings of swallowing abnormalities under videofluoroscopic examination in the form of delayed swallowing reflex and vallecular residue (107). In another study with 25 patients with cervical dystonia, 72% had dysphagia based on electrophysiological evaluation (49).

Extra cervical involvement is not uncommon in cervical dystonia. In an analysis of 1477 patients with cervical dystonia, 60.7% did not develop any other type of abnormal movements (97). On the other hand, 17.9% who initially had cervical dystonia, developed dystonia in other areas, most commonly hands, face, and head. One study demonstrated that 28% of patients diagnosed with focal cervical dystonia also had one other body part affected in addition to the neck. The most common site was the shoulder, followed by hand, face, and larynx. Movement disorder specialists often diagnosed focal cervical dystonia as dystonia isolated to the neck or the neck and a shoulder, whereas dystonia affecting the neck and the arm, face, jaw, or larynx was diagnosed as a segmental dystonia (71). Postural hand tremor or head tremor are more common associations. Tremor was noted in 63% of patients with isolated focal or segmental cervical dystonia, and the spread of dystonia commonly occurs in areas affected by the tremor (97). In fact, patients presenting with head tremor as the primary manifestation of cervical dystonia may have a tremor-dominant subtype of cervical dystonia with evidence of cerebellar dysfunction as demonstrated by greater cerebellar disability scores on the Scale for the Assessment and Rating of Ataxia (SARA), increased gait variability, and reduced cerebellar vermian volume (86). Hand tremor is seen in at least 30% of patients and usually manifests with symmetrical postural and action tremor (22). Whether the hand tremor in cervical dystonia is a manifestation of dystonia or coexisting essential tremor is a matter of debate (112). Notably, the co-occurrence of dystonia, especially cervical dystonia, in families with essential tremor was reported (83).

The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), a comprehensive cervical dystonia rating scale has been found to be internally consistent and potentially useful as an outcome measure for therapeutic trials of cervical dystonia (35). In the CD-PROBE study, the minimal clinically important change (MCIC) on TWSTRS for improvement was noted to be ≥8 points based on mean TWSTRS total scores in patients with cervical dystonia when compared against the Patient Global Impression of Change (41).

Prognosis and complications

Spontaneous remission occurs in about 10% to 20% of patients (61; 22), usually taking place within the first year of symptoms and with decreasing frequency as the illness becomes more chronic. In general, younger patients are more likely to have spontaneous remission, and the occurrence of remission falls off exponentially after 5 years.

The natural course of cervical dystonia is not well described, though most experts agree that symptoms tend to worsen in the first 5 to 10 years after onset after which it usually remains stable (02).

Cervical dystonia can worsen quality of life and may be associated with depression and other mood changes. Psychiatric features and level of pain seem to be the main determinants of disability (127). One study showed that even with effective pain relief in cervical dystonia with botulinum toxin use, mood symptoms, such as depression and anxiety, remained unchanged, suggesting that cervical dystonia is more than just a motor disorder (92). An international survey of patients with cervical dystonia reported that although the majority were satisfied with their relationship with their physician, they often had high expectations from treatment, hoping to be free from spasms and pain and return to their normal routine (32). Educating patients about the natural history of cervical dystonia and reasonable expectations from therapy is an important part of the treatment plan.

Given that the onset of cervical dystonia in most patients is in the 4th or 5th decade, it is not surprising that employment and work productivity have been found to be negatively affected even in treated patients (91). Pain has been found to be a primary driver of these adverse impacts, and preliminary evidence suggests that initiating treatment with onabotulinumtoxinA may reduce absenteeism and presenteeism (reduced productivity).

Clinical vignette

A 48-year-old woman presented with a seven-year history of involuntary head rotation to the right, which was persistent throughout the day and was associated with superimposed bouts of forceful spasms that would throw her head backward. The involuntary movements were worse when she was nervous or in front of a crowd. She felt that using her hand to touch her chin would partially relieve her symptoms, allowing her to maintain her head straight for a short period of time. She had severe pain in her neck on the right side. She was a telephone operator and had stopped working for 3 years because of this condition. She admitted that she was depressed.

On examination, she looked anxious. Her head posture was abnormal, being held to the right. There were episodic quick jerky movements of her head being pulled backward. Her left sternocleidomastoid muscle appeared hypertrophic. She was able to partially correct the head posture by touching her chin with her right hand. There was a fine hand tremor of her outstretched hands. The rest of her examination was normal.

Routine blood tests were normal. X-rays of her cervical spine revealed abnormal head and neck posturing and early changes of cervical spondylosis. CT scan of her head was normal.

A diagnosis of cervical dystonia was made. She was subsequently treated with botulinum toxin injections given intramuscularly to her neck muscles. Her left sternocleidomastoid, right splenius capitis, and right levator scapulae were treated. She reported improvement in her head posturing and a reduction in neck pain after 3 days, and clinical response lasted 10 weeks. She was treated with repeated injections every 3 to 4 months and continued to respond favorably to the treatment.

Biological basis

Etiology and pathogenesis

The etiology of cervical dystonia remains unknown but appears to be heterogeneous. Genetic causes and a relationship to trauma have been studied. In terms of underlying neurophysiology, dystonia has been considered to be a network disorder and involves basal ganglia, cerebellum, pedunculopontine nucleus, thalamus, and cortex (68; 122; 89).

Genetics. The role of inheritance is poorly defined. Although the majority of cases are sporadic, a family history of dystonia may be found in some patients. In a review of 1000 patients with idiopathic cervical dystonia, 14% of patients reported a family history (76). A handful of variant genes have been identified in patients with cervical dystonia, but they are disease-causing only in a small percentage of patients.

DYT7 gene locus on chromosome 18p has been associated with families from Germany and Central Europe with cervical dystonia (77), but the significance of this association has been questioned (131). The DYT13 gene locus has been described in idiopathic torsion dystonia, presenting with predominantly craniocervical and upper limb dystonia in an Italian family (126). Polymorphism in the dopamine D5 receptor gene has been reported to link with the development of cervical dystonia, suggesting a candidate gene at the DRD5 locus (15). The contribution of polymorphism Val66Met in the gene encoding brain-derived neurotropic factors (BDNF) for the pathogenesis of dystonia was debated, but a meta-analysis that pooled 784 patients with dystonia and 1020 controls supported a true association (109).

More convincing and potentially monogenetic causes of the cervical dystonia phenotype are also now supported in the literature. Over 50 families have been described with mutations in DYT6 (encoding for THAP1, a proapoptotic protein), with dystonia primarily affecting the cervical, cranial, and upper limb muscles (14). THAP1 mutations decrease transcription regulation and DNA binding (106). It also interferes the myelination within the oligodendrocyte lineage, which may implicate abnormal timing of myelination with dystonia. A mutation was found in exon 7 of CIZ1 (c.790A> G, p.S264G) in a large Caucasian pedigree with adult-onset cervical dystonia using whole-exome sequencing (134). CIZ1 encodes CIZ1 (Cip1-interacting zinc finger protein 1) involved in DNA synthesis and cell cycle control. A study of 12 Chinese probands with familial cervical dystonia failed to identify a mutation in CIZ1 (84). Another study of 45 Chinese patients with isolated cervical dystonia found mutations in the COL6A3 gene, suggesting an autosomal recessive cause of early-onset isolated dystonia (133). This gene encodes the collagen alpha-3 chain, which is one of the three subunits of collagen type IV. Mutations in GNAL have been found to be a cause of primary torsion dystonia in several families, with the neck as a common site of onset (55; 74; 21). GNAL encodes the protein Gαolf, which is important for dopamine D1 receptor function. However, a study with 192 British probands failed to identify GNAL mutations as the causative gene for cervical dystonia (25). Mutations in the anoctamin3 gene (ANO3) have been associated with autosomal dominant craniocervical dystonia (26). The gene encodes a calcium-gated chloride channel, which is highly expressed in the striatum. The most common site of onset was the neck. Head and hand tremors were frequently present, but myoclonus was only occasionally seen. DYT-TUBB4A, formerly known as DYT4 of “whispering dysphonia,” involves mutations to TUBB4A, with the most consistent feature being laryngeal involvement though cervical dystonia was seen in 60% of the reported cases (05).

In a multicentric cohort involving 1000 patients with cervical dystonia, the contribution of known genes to cause dystonia was small. Pathogenic or likely pathogenic sequence variants of GNAL, TAHP1, and TOR1A were found in 0.8% of the participants (76). Synonymous and noncoding sequence variants in THAP1 and GNAL were found in 4% of the patients. In the largest genome-wide association study (GWAS) of cervical dystonia to date, which included 919 patients and 1491 controls, no variants were found that could be validated in a replication study (121). Based on these studies, a very small percentage of patients with cervical dystonia have monogenic disease. The majority of patients are likely to have a combination of multiple risk-modifying sequence variants and exposure to environmental contributors.

Metabolomics. Metabolomics may offer additional insight into the pathophysiology of cervical dystonia. The metabolome reflects the combined systemic effects of genetics, lifestyle, environmental exposure, and secondary biological responses. One study identified nine biological processes associated with cervical dystonia, including oxidized lipid 2-hydroxydecanoate, which may be abnormal in cervical dystonia (80).

Trauma. The role of trauma in the pathogenesis of cervical dystonia is unclear. Clinically, torticollis occurring shortly after neck injury differs from typical idiopathic cervical dystonia in that usually no improvement appears during or after sleep, and no help is provided by "sensory tricks" (125). Patients who develop cervical dystonia immediately after a relatively mild neck injury have been described (57), but the significance remains unclear. In another report, however, 12% of patients developed symptoms similar to classical cervical dystonia shortly after head or neck injury (110). These patients had an earlier age of onset with a higher prevalence of neck pain and might reflect a triggering effect of trauma on patients who were predisposed to the development of cervical dystonia. Consistently, a subgroup of patients exists: those who present with symptoms quickly after trauma (with severe pain being a major symptom), have fixed torticollis with a greater tendency for laterocollis, and are resistant to treatment (108; 98). It has been proposed that the disorder should be called “posttraumatic painful torticollis” to differentiate these patients from those with the usual form of the disorder (108).

Pathophysiology. Despite the advances in the last 20 years in identifying genes that are present in patients with cervical dystonia, there is an important gap in knowledge of how those changes translate to abnormal function of higher-order motor control that generates dystonic symptoms (16). Mutant mice for TOR1A have impaired formation of afferent synapsis in a set of interneurons called GABApre (135). Those interneurons are located in the dorsal spinal cord and inhibit proprioceptive sensory afferent terminals, and they negatively regulate sensory-motor signaling. Changes in brain circuits are also implicated in the genesis of cervical dystonia. A meta-analysis of studies with voxel-based morphometry of gray matter volume in individuals with primary focal dystonia showed changes in the post-central gyrus, primary motor cortex, thalamus, and putamen, which implicates structural abnormalities in the sensorimotor network (136). Another study of functional MRI and cervical dystonia implicated other areas of the brain, including dorsal cingulate gyrus, cerebellum, and different areas of the frontal lobe (79). A postmortem neuropathological study in six cervical dystonia brains revealed a significantly lower density of Purkinje cell density in the cerebellum compared to controls, suggesting possible cerebellar dysfunction in cervical dystonia (104). Another study with 188 patients with cervical dystonia showed that 14% had clinical or radiological evidence of cerebellar involvement (07). Finally, a study of 32 patients with cervical dystonia showed significant reductions in diffusion tensor imaging (DTI)-based tractography, suggesting microstructural abnormalities within dentatorubrothalamic tracts consistent with decreased axonal integrity (116). This is suggestive of abnormal functional connectivity between the cerebellum and somatosensory cortex.

The presence of alleviating maneuvers also indicates a dysfunction of sensorimotor integration. Data from a primate model of dystonia show that there are enlarged and overlapped sensory receptive fields (117). Positron emission tomography studies on the alleviating maneuvers reported on ipsilateral (to direction of head turn) superior and inferior parietal lobe as well as bilateral occipital cortex activation associated with reduction of activities in the contralateral supplementary motor areas and primary sensorimotor cortex (13). Evidence expands on this important role of dysfunction in sensorimotor cortex, including defective inhibitory plasticity (48), abnormal sensory gating (38), and impaired cortical modulation of brainstem circuits (100).

Differential diagnosis

Confusing conditions

There is often a delay in the diagnosis of cervical dystonia. In one study, a total of 108 patients saw a mean of 3.5 providers over a mean period of 44 months from symptom onset to diagnosis (123). Cervical dystonia should be distinguished from an isolated head tremor that can be seen in essential tremor. In contrast to essential tremor, cervical dystonia is associated with an abnormal posture, tends to be irregular, and is associated with a null point (a particular head position that attenuates the tremor).

Secondary causes of torticollis should be excluded before reaching a diagnosis of idiopathic cervical dystonia (120; 75). Secondary causes include structural lesions, drug exposures, neurodegenerative diseases such as Parkinson disease, multiple system atrophy, and progressive supranuclear palsy. Congenital or traumatic bony abnormalities in the cervical spine may be detected by x-rays of the region. Septic arthritis of C1 to C2 lateral facet joint, pharyngeal abscess, cervical epidural abscess, and osteomyelitis have been reported to present with torticollis.

A variety of tumors, including cerebellar cavernous angioma, frontal meningioma, posterior fossa tumor, and spinal astrocytoma or ependymoma, have all been reported to present as torticollis.

In children, one should be aware of the condition known as Sandifer syndrome, in which tilting of the head may relieve pain associated with a hiatal hernia. Congenital shortening and fibrosis of the sternocleidomastoid muscle may present in infancy as torticollis. This may sometimes be associated with congenital vertebral anomalies.

Ocular causes may produce head tilting as a compensatory act for diplopia. Trochlear nerve palsy is an example, but head tilting can occur in other ocular muscle palsies. Similarly, patients with vestibular diseases may tilt their heads to find the position with least vertigo.

Rare causes of torticollis include basal ganglia infarction, systemic lupus erythematosus, psoriatic spondylitis, midbrain lesion in multiple sclerosis, and ataxia-telangiectasia.

Cervical dystonia can be caused by exposure to dopamine receptor-blocking agents such as neuroleptics and antiemetics (56). Tardive cervical dystonia should be suspected in the setting of such medication exposure. In one cross-sectional study, clinical features such as predominant retrocollis and extra cervical involvement were associated with tardive cervical dystonia whereas predominant torticollis, head tremor, sensory trick, and family history were associated with idiopathic cervical dystonia (90). There have also been isolated reports of cervical dystonia caused by cholinesterase inhibitors such as donepezil (60).

Management

Botulinum toxin. Botulinum toxin injected intramuscularly into the dystonic neck muscles is helpful in relieving symptoms of cervical dystonia and is considered a first-line treatment for this disorder (01; 62; 103). Type A (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA) and type B (rimabotulinumtoxinB) formulations of botulinum toxin are approved for the treatment of cervical dystonia (115). This toxin prevents the release of acetylcholine at nerve terminals and induces temporary, graded weakness in the dystonic muscles with improvement in head posture, involuntary movements, and pain. Botulinum toxin has also been shown to improve depression and anxiety in patients with cervical dystonia (39). The available formulations of botulinum toxin have been extensively evaluated in clinical trials, demonstrating significant improvement in cervical dystonia compared to placebo (78; 124; 34; 23).

Anterocollis is often excluded from clinical trials of botulinum toxin because it is presumed that this treatment is not effective; however, some patients clearly improve with injections, although the risk of dysphagia is higher than with other forms of cervical dystonia (63). However, one study found that targeting muscles such as longus colli, longus capiti, suprahyoid muscles (predominantly the anterior heads of the digastric), and the sternocleidomastoid muscles could be targeted in anterocollis, with benefit reported by patients (88). Injection of these muscles remains technically challenging. This study utilized ultrasound combined with EMG guidance for injections into the longus colli muscles and aid from an ENT using an endoscopic approach via the nose to inject the longus capiti muscles. The side effects of botulinum toxin when treating cervical dystonia include dysphagia, flu-like symptoms, and neck weakness. Based on pivotal trials, the general recommendation is that botulinum toxin be administered no sooner than every 3 months; however, the optimal dosing frequency is still being investigated.

One posthoc analysis evaluated flexible dosing of incobotulinumtoxinA at intervals ranging from six to 20 weeks in patients with cervical dystonia, based on patient request and clinical examination (50). Intervals between injections were less than 12 weeks in 369 of 821 (44.9%) treatment cycles for cervical dystonia. The severity and frequency of adverse events were similar in subjects receiving injections at intervals less than 12 weeks compared 12 weeks or more. The most common side effects were dysphagia, muscular weakness, neck pain, and injection-site pain. This study evaluated up to six treatment sessions and, thus, long-term studies are needed to assess the development of immunoresistance with chronic therapy at shorter intervals. A study utilizing incobotulinumtoxinA, showed that patients with cervical dystonia who experience early waning of incobotulinumtoxinA effect benefit from shorter injection cycles without an increased risk of side effects or loss of benefit over time (33).

With the potential advantage of a longer duration of response, injectable DaxibotulinumtoxinA is in development as an alternative to currently available botulinum toxins. In an open-label, dose-ranging, phase 2 study, the median duration of response in 33 subjects was nearly 6 months (65).

There is no clear consensus on the optimal injection technique for botulinum toxin; however, an injection plan is generally based on head position, location of pain, and presence of hypertrophy in muscles likely to contribute to the observed head position. Despite differences in technique among practitioners, there is general agreement that it is best to use the lowest effective dose at each treatment session and only repeat injections as often as necessary.

Muscles are targeted for injection based on a variety of factors including the direction of head position. The classic head positions along with most common muscles injected include torticollis (splenius, levator scapulae, semispinalis, contralateral sternocleidomastoideus), laterocollis (levator scapulae, semispinalis, scalenus medius), retrocollis (bilateral semispinalis), and anterocollis (bilateral sternocleidomastoideus, bilateral levator scapulae) (69). Injection of more anterior muscles can cause dysphagia when doses are too high, so great caution should be exercised. To further help with targeting muscles, the injector will often rely on EMG activity as well as muscle palpation, feeling for tenderness and muscle hypertrophy. Whether automated kinematic assessments can improve on injection plans based on traditional examination methods is a subject of investigation (111). Jost and colleagues proposed a system (Col-Cap concept) that further subdivides head positions by differentiating caput from collis. Collis involves neck movement above C2, whereas with caput, the neck remains fixed above C2. For example, torticollis can be subdivided as torticaput (no upper neck rotation) or torticollis (includes upper neck rotation) (69). They further propose muscle injection patterns according to these subdivisions. At this time, it is unclear if this approach will improve outcomes.

Oral medications. Various oral agents are commonly used in clinical practice in off-label fashion. However, there are limited data to support the use of oral medications for the treatment of cervical dystonia (103). Anticholinergic drugs such as trihexyphenidyl have been described to be effective in a small number of patients. Baclofen, a GABA B receptor agonist, may be helpful in some patients as well. Benzodiazepines, such as lorazepam and clonazepam, can also be helpful. Rarely, levodopa has been found to ameliorate cervical dystonia in patients with adult-onset dopa-responsive dystonia (113). These agents are often limited by side effects but may be helpful as an adjunct treatment with botulinum toxin.

Other agents have been tried in botulinum toxin–refractory cervical dystonia, such as riluzole, a medicine aimed at antagonizing glutamatergic action in the basal ganglia. A six-patient, open-label study showed clinical improvement in half the patients, but these results have not been replicated in controlled clinical trials (93). Perampanel, an antiseizure agent that antagonizes AMPA receptors, was evaluated in an open-label phase 2a study (54). At doses typical of its use in epilepsy, perampanel was poorly tolerated and showed no motor benefit for motor symptoms of cervical dystonia.

Deep brain stimulation. Deep brain stimulation can be helpful for patients with cervical dystonia who are refractory to other treatments. A prospective study of bilateral GPi deep brain stimulation in 10 patients with cervical dystonia found a significant clinical improvement based on blinded assessments after a mean of 7.7 years (129). All 10 patients had 5 years of open-label follow-up with significant improvement. A study of GPi deep brain stimulation in cervical dystonia involving 28 patients found that neither advanced age nor severity of symptoms was associated with a poor response (132). However, those patients with lateral shift had less improvement. A multicenter, randomized, sham-controlled study evaluated the efficacy of GPi deep brain stimulation for the treatment of cervical dystonia (128). This trial involved 62 patients, and the primary endpoint was the change in the TWSTRS severity score from baseline to 3 months, assessed by two blinded dystonia experts. At 3 months, there was significant improvement in severity for the deep brain stimulation group compared to sham stimulation (-5.1 points vs. -1.3, p=0.0024). There were also significant improvements in the TWSTRS disability score (41% vs. 11%) and Bain Tremor Score (61% vs. 16%) in the stimulation group compared to the sham group. There were no significant differences between groups in improvement of measures of pain and quality of life. A retrospective study of 30 patients with primary cervical dystonia treated with GPi deep brain stimulation demonstrated that those with a phasic type had greater response than those with a tonic-type of dystonia (28). More specifically, they propose that the range of voluntary neck motility with respect to midline is an objective factor that is useful in predicting the prognosis of patients with cervical dystonia who undergo deep brain stimulation surgery. Patients who could move their heads past midline presurgery showed an average TWSTRS improvement of 73.9% compared to 55.3% for the group that could not move their heads past midline (59). There is also evidence of benefit from GPi deep brain stimulation in patients with cervical dystonia who previously underwent peripheral denervation surgery (20). A small study with 13 patients evaluated cognition after 12 months of continuous stimulation (46). There was minimal impact in the number of produced words. The other cognitive domains were intact, supporting that deep brain stimulation seems a safe treatment modality.

Another small study used functional MRI to evaluate the amplitude of low frequency fluctuations (ALFF) in patients with bilateral GPi deep brain stimulation at a priori clinically optimal settings, nonoptimal settings, and with the device off. ALFF has been shown to reflect the intensity of spontaneous neural activity. All patients showed significantly decreased ALFF in the primary motor cortex and somatosensory cortex comprising leg, trunk, and arm regions with optimal settings compared to the off state. Decreased ALFF in the sensorimotor cortex and increased ALFF in the pons were seen in optimal settings compared to nonoptimal settings. This suggests that optimized GPi deep brain stimulation normalizes aberrant sensorimotor cortex hyperactivity in dystonia (82).

A separate investigation observed patients who underwent bilateral GPi deep brain stimulation (70). It showed improvement in the TWSTRS scores for disease severity, disability, and pain by 72%, 59%, and 46%, respectively. These benefits persisted up to 5 years after the initial surgery, though there has been little other long-term data published to confirm these findings.

Subthalamic nucleus deep brain stimulation has been explored as an alternative target because of observations of parkinsonian signs, such as bradykinesia in patients with cervical dystonia treated with pallidal stimulation (87). In a series of nine patients assessed with blinded rating scales (TWSTRS), bilateral subthalamic stimulation appeared to be an effective alternative (99). Side effects observed were depression and weight gain, but there was no bradykinesia observed.

Experience with the recording of oscillatory activity in neurons during deep brain stimulation surgery has led to the identification of increased beta synchronization as a physiomarker in Parkinson disease, and current efforts have focused on taking advantage of this to develop responsive closed-loop deep brain stimulation systems to treat this disorder. Similarly, an investigation in cervical dystonia may have identified abnormal theta activity in the internal pallidum as a useful physiomarker that could be of use in future development of responsive deep brain stimulation treatment of cervical dystonia (95).

Other surgical procedures. Selective peripheral denervation has been performed in limited numbers of patients with cervical dystonia and appears to be modestly beneficial. This surgical procedure involves sectioning of the nerve twigs supplying the dystonic neck muscles (11). This operation may be considered for patients who are resistant to all other forms of therapy. In a series of 168 patients, 77% had a moderate to excellent improvement in head position, and pain improved in 81% (30). These results were sustained for a follow-up period of 3.4 years in 70% of those who improved. A review of selective peripheral denervation in 53 patients with cervical dystonia evaluated clinical outcomes postoperatively, at 6 months, and at a mean of 42 months (10). All except three patients were secondary nonresponders to botulinum toxin. Follow-up was available for 55 procedures at 6 months and 34 procedures at late follow-up. Statistically significant improvements were seen at both time points in the Tsui scale score and in a Visual Analogue Scale. The major postoperative issues included recurrence of dystonia with a change in muscles involved (51%) and reinnervation of muscles (43%). Clinical symptoms of major concern were seen after 29% of procedures, and 13% of patients had repeat denervations. Thus, although selective peripheral denervation can result in improvement of symptoms and quality of life, the risk of return of symptoms needs to be taken into consideration. A retrospective study evaluating the long-term outcome of selective peripheral denervation in comparison to bilateral GPi deep brain stimulation for cervical dystonia included 35 patients who had at least one year of follow-up (37). Eleven patients who underwent selective peripheral denervation needed additional surgery due to insufficient benefit, whereas only one patient with deep brain stimulation needed a second surgery for repositioning of electrodes. The combined global surgical outcome score for selective peripheral denervation versus deep brain stimulation was “bad” in 65 and 13.3%, “fair to good” in 30 and 26.7%, and marked improvement in five and 60% (p < 0.001). Side effects were reported in 75% of selective peripheral denervation patients and 60% of deep brain stimulation patients and were not significantly different. The most common side effects were sensory disturbance in the selective denervation patients and hardware complications and speech changes in the deep brain stimulation patients. One deep brain stimulation patient had an intraoperative hemorrhage.

Noninvasive neuromodulation. Some noninvasive neuromodulation methods have been described and may offer therapeutic techniques to correct abnormal excitatory circuits in cervical dystonia. These include repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) (81). It has been shown that the cerebellum and its circuits seem to play a role in the pathogenesis of cervical dystonia. One study used cerebellar continuous theta burst stimulation (cTBS), a novel form of repetitive transcranial magnetic stimulation, in an attempt to activate synaptic plasticity in the cerebellar-thalamo-cortical circuits. Evaluation after 2 weeks of cerebellar stimulation demonstrated improvement for patients with cervical dystonia in the TWSTRS scale. The effect of transcranial direct current stimulation in patients with cervical dystonia is still being studied (72).

Physical therapy. Although physical therapy may be helpful as adjunctive therapy for cervical dystonia, the studies evaluating its efficacy have been limited. A systematic literature review of physical therapy as a treatment for cervical dystonia included 16 studies (45). Seven were clinical trials, and the remaining were case reports or case series. Most studies were of low methodological quality, and the limitations included a small sample size and a lack of randomization and blinding. Reported treatments include EMG biofeedback training, transcutaneous electrical nerve stimulation, muscle elongation, massage, and relaxation training. Although there are reports of improved head position, range of motion, pain, and quality of life, further high-quality studies are needed to determine the efficacy of physical therapy for cervical dystonia. One randomized trial showed no statistically or clinically significant benefit from specialized physiotherapy compared to standard neck physiotherapy (40).

Outcomes

A retrospective, longitudinal descriptive study evaluated the long-term benefit and side effect profile of botulinum toxin for 89 patients with dystonia, including 51 patients with cervical dystonia (105). Long-term therapeutic benefit was maintained with a mean follow-up of 18.5 years. This retrospective analysis was limited to only those patients who had been receiving botulinum toxin injections regularly for at least 10 years at a single movement disorder center. Comparing the benefit after last injection with first injection, there was an improvement in global response effect (3.57 vs. 3.18, p < 0.0001), greater peak effect on dystonia (3.75 vs. 3.45, p < 0.0005), shorter latency to effect (3.3 days vs. 5.5 days, p < 0.0001), longer duration of maximal (15.78 vs. 13.45, p = 0.0084), and total benefit (19.42 vs. 16.33, p = 0.0037). Adverse events were reported in 10% of patients with cervical dystonia; the most common side effects were dysphagia and neck weakness. Overall, this report provides support for the long-term efficacy and safety of botulinum toxin for the treatment of dystonia.

Another prospective, observational study demonstrated a reduction in objective cervical dystonia severity in patients receiving onabotulinumtoxinA injections that was sustained over the duration of the study (36 months). TWSTRS scores continued to improve during this period, from 31.59 at baseline, to 27.52 at 12 months, 25.79 at 24 months, and 24.49 at 36 months. Furthermore, the study demonstrated patient satisfaction scores between 88% to 90% throughout the duration of the study (31). The study shows high rates of both objective improvement and subjective satisfaction. Of note, subjective improvement remained stable despite objective improvement over time, suggesting that there is some degree of dissociation between the two measures.

The development of neutralizing antibodies and loss of clinical response to botulinum toxin is a potential long-term problem. This makes sense given the repeated injection of a large protein over time akin to a vaccine, but the risk is felt to be offset by the minute amount of toxin being injected (nanograms). Assessing immunity through antibody testing is problematic. Antibodies detected by ELISA are not necessarily neutralizing, and the more specific mouse protection assay is not readily available. In addition, multiple factors can lead to secondary treatment failure other than immunoresistance. Looking at this issue, a review of 39 patients identified the following causes of unsatisfactory response: suboptimal doses and muscle targeting, intolerable side effects, complex movement patterns, discordant perceptions, and incorrect diagnoses (67). Only one patient had true immunoresistance

Regarding the true incidence of neutralizing antibody-mediated toxin resistance, historical estimates have been quite low. One early study found four of 326 (1.2%) patients with cervical dystonia had true neutralizing antibodies (17). A meta-analysis looking across different indications at over 2000 patients treated with onabotulinumtoxinA exclusively found a similar low overall frequency of conversion to antibody positivity in 0.49% and in cervical dystonia specifically of 1.28% (94). However, a much higher prevalence than expected was found in a current study looking at 596 patients with cervical dystonia as well as other dystonia subtypes treated at least four times with botulinum toxin type A (03). Overall, 13.9% had neutralizing antibodies by mouse protection assay. Factors that were associated with a higher risk of developing antibodies were higher individual and cumulative dose of toxin; botulinum toxin formulation with incobotulinumtoxinA was associated with the lowest risk. Unfortunately, this study suffers from several flaws (08). For example, the majority of the 596 patients were treated with abobotulinumtoxinA, which has a higher protein content than the other types of botulinum neurotoxin and, hence, may account for the greater antigenicity. The authors fail to mention other studies showing a much lower frequency of neutralizing antibodies (17). They provide no data on the correlation between the presence of antibodies detected by hemidiaphragm assay and clinical response, although they state that their patients were “still responding.” In contrast, none of our patients with positive titers for blocking antibodies tested by mouse protection assay had any clinical response, indicative of true immunoresistance. Mouse protection assay is more clinically meaningful as it correlates well with clinical response, which may explain the differences in the reports of secondary unresponsiveness among various studies using different assays and botulinum neurotoxin products (58). There is clearly a need to develop more sensitive and specific assays for neutralizing antibodies and to provide correlative analyses of the titers and lack of clinical response (09).

In practice, patients who have developed immunoresistance to botulinum toxin A can be switched to botulinum toxin type B with re-establishment of a clinical response. One report found that eight subjects who had developed immunoresistance to abobotulinumtoxinA or onabotulinumtoxinA were able to re-establish clinical responsivity to incobotulinumtoxinA after a one-year hiatus from treatment (47). This response was sustained over 2.5 years without an elevation in antibody titers, and it was proposed that this was possible due to the “low antigenicity” of incobotulinumtoxinA.

References

01: Albanese A, Abbruzzese G, Dressler D, et al. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol 2015;262(10):2201-13. PMID 25877834
02: Albanese A, Bhatia KP, Cardoso F, et al. Isolated cervical dystonia: diagnosis and classification. Mov Disord 2023;38(8):1367–78. PMID 36989390
03: Albrecht P, Jansen A, Lee J, et al. High prevalence of neutralizing antibodies after long-term botulinum toxin therapy. Neurology 2019;92:e48-54. PMID 30464031
04: Amadio S, Houdayer E, Bianchi F, et al. Sensory tricks and brain excitability in cervical dystonia: a transcranial magnetic stimulation study. Mov Disord 2014;29(9):1185-8. PMID 24753013
05: Bally JF, Kern DS, Fearon C, et al. DYT-TUBB4A (DYT4 dystonia): clinical anthology of 11 cases and systematized review. Mov Disord 2022;9(5):659-75. PMID 35844288
06: Barbanti P, Fabbrini G, Pauletti C, Defazio G, Cruccu G, Berardelli A. Headache in cranial and cervical dystonia. Neurology 2005;64(7):1308-9. PMID 15824376
07: Batla A, Sanchez MC, Erro R, et al. The role of cerebellum in patients with late onset cervical/segmental dystonia?--evidence from the clinic. Parkinsonism Relat Disord 2015;21(11):1317-22. PMID 26385708
08: Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins (Basel) 2019;11(9). PMID 31454941
09: Bellows S, Jankovic J. Reply to comment on re-visiting immunogenicity associated with botulinum toxin treatment. Toxins (Basel) 2020;12(2). PMID 31979241
10: Bergenheim AT, Nordh E, Larsson E, Hariz MI. Selective peripheral denervation for cervical dystonia: long-term follow-up. J Neurol Neurosurg Psychiatry 2015;86(12):1307-13. PMID 25362089
11: Bertrand CM, Molina-Negro P. Selective peripheral denervation in 111 cases of spasmodic torticollis: rationale and results. In: Fahn S, Marsden CD, Calne DB, editors. Dystonia 2. New York: Raven, 1988;50:637-43.
12: Bezerra ME, Rocha-Filho PA. Headache attributed to craniocervical dystonia - a little known headache. Headache 2017;57(2):336-43.** PMID 27910093
13: Bhidayasiri R, Bronstein JM. Improvement of cervical dystonia: possible role of transcranial magnetic stimulation simulating sensory tricks effect. Med Hypotheses 2005;64(5):941-5. PMID 15780489
14: Blanchard A, Ea V, Roubertie A, et al. DYT6 dystonia: review of the literature and creation of the UMD Locus-Specific Database (LSDB) for mutations in the THAP1 gene. Hum Mutat 2011;32(11):1213-24. PMID 21793105
15: Brancati F, Valente EM, Castori M, et al. Role of the dopamine D5 receptor (DRD5) as a susceptibility gene for cervical dystonia. J Neurol Neurosurg Psychiatry 2003;74(5):665-6. PMID 12700316
16: Breakefield XO, Blood AJ, Li Y, Hallett M, Hanson PI, Standaert DG. The pathophysiological basis of dystonias. Nat Rev Neurosci 2008;9(3):222-34. PMID 18285800
17: Brin MF, Comella CL, Jankovic J, et al. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 2008;23(10):1353-60. PMID 18546321
18: Broussolle E, Laurencin C, Bernard E, Thobois S, Danaila T, Krack P. Early illustrations of geste antagoniste in cervical and generalized dystonia. Tremor Other Hyperkinet Mov (N Y) 2015;5:332. PMID 26417535
19: Brucker MC, King TL. The 2015 US Food and Drug Administration pregnancy and lactation labeling rule. J Midwifery Womens Health 2017;62(3):308-16. PMID 28556499
20: Capelle HH, Blahak C, Schrader C, et al. Bilateral deep brain stimulation for cervical dystonia in patients with previous peripheral surgery. Mov Disord 2012;27(2):301-4. PMID 22173964
21: Carecchio M, Panteghini C, Reale C, et al. Novel GNAL mutation with intra-familial clinical heterogeneity: expanding the phenotype. Parkinsonism Relat Disord 2016;23:66-71. PMID 26725140
22: Chan J, Brin MF, Fahn S. Idiopathic CD: clinical characteristics. Mov Disord 1991;6(2):119-26. PMID 2057004
23: Charles D, Brashear A, Hauser RA, et al. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharm 2012;35(5):208-14. PMID 22948497
24: Charles PD, Adler CH, Stacy M, et al. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol 2014;261(7):1309-19. PMID 24752807
25: Charlesworth G, Bhatia KP, Wood NW. No pathogenic GNAL mutations in 192 sporadic and familial cases of cervical dystonia. Mov Disord 2014;29(1):154-5. PMID 24222099
26: Charlesworth G, Plagnol V, Holmstrom KM, et al. Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis. Am J Hum Genet 2012;91(6):1041-50. PMID 23200863
27: Chawda SJ, Munchau A, Johnson D, et al. Pattern of premature degenerative changes of the cervical spine in patients with spasmodic torticollis and the impact on the outcome of selective peripheral denervation. J Neurol Neurosurg Psychiatry 2000;68(4):465-71. PMID 10727482
28: Chung M, Huh R. Different clinical course of pallidal deep brain stimulation for phasic- and tonic-type cervical dystonia. Acta Neurochir (Wien) 2016;158(1):171-80. PMID 26611690
29: Claypool DW, Duane DD, Ilstrup DM, Melton LJ 3rd. Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, Minnesota. Mov Disord 1995;10(5):608-14. PMID 8552113
30: Cohen-Gadol AA, Ahlskog JE, Matsumoto JY, Swenson MA, McClelland RL, Davis DH. Selective peripheral denervation for the treatment of intractable spasmodic torticollis: experience with 168 patients at the Mayo Clinic. J Neurosurg 2003;98(6):1247-54. PMID 12816272
31: Colosimo C, Charles D, Misra VP, Maisonobe P, Om S, INTEREST IN CD2 Study Group. How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study. J Neurol 2019; 266(12):3038-46. PMID 31501975
32: Comella C, Bhatia K. An international survey of patients with cervical dystonia. J Neurol 2015;262(4):837-48. PMID 25605434
33: Comella C, Hauser RA, Isaacson SH, et al. Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority study. Clin Park Relat Disord 2022;6:100142. PMID 35330880
34: Comella CL, Jankovic J, Truong DD, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurological Sci 2011;308:103-9. PMID 21764407
35: Comella CL, Perlmutter JS, Jinnah HA, et al. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord 2016;31(4):563-9. PMID 26971359
36: Contarino MF, Van Den Dool J, Balash Y, et al. Clinical practice: evidence-based recommendations for the treatment of cervical dystonia with botulinum toxin. Front Neurol 2017;8:35. PMID 28286494
37: Contarino MF, Van Den Munckhof P, Tijssen MA, et al. Selective peripheral denervation: comparison with pallidal stimulation and literature review. J Neurol 2014;261(2):300-8. PMID 24257834
38: Conte A, Belvisi D, De Bartolo MI, et al. Abnormal sensory gating in patients with different types of focal dystonias. Mov Disord 2018;33(12):1910-7. PMID 30403835
39: Costanzo M, Belvisi D, Berardelli I, et al. Effect of botulinum toxin on non-motor symptoms in cervical dystonia. Toxins (Basel) 2021;13(9):647. PMID 3464651
40: Counsell C, Sinclair H, Fowlie J, et al. A randomized trial of specialized versus standard neck physiotherapy in cervical dystonia. Parkinsonism Relat Disord 2016;23:72-9. PMID 26723272
41: Dashtipour K, Mari Z, Jankovic J, Adler CH, Schwartz M, Brin MF. Minimal clinically important change in patients with cervical dystonia: results from the CD PROBE study. J Neurol Sci 2019;405:116413. PMID 31494402
42: Defazio G, Belvisi D, Comella C, et al. Validation of a guideline to reduce variability in diagnosing cervical dystonia. J Neurol 2023; 270(5):2606-12. PMID 36790546
43: Defazio G, Jankovic J, Giel JL, Papapetropoulos S. Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet Mov (N Y) 2013;3. PMID 24255801
44: Dehring DJ, Gupta B, Peruzzi WT. Postoperative opisthotonus and torticollis after fentanyl, enflurane, and nitrous oxide. Can J Anaesth 1991;38(7):919-25. PMID 1742831
45: De Pauw J, Van der Velden K, Meirte J, et al. The effectiveness of physiotherapy for cervical dystonia: a systematic literature review. J Neurol 2014;261(10):1857-65. PMID 24413637
46: Dinkelbach L, Mueller J, Poewe W, et al. Cognitive outcome of pallidal deep brain stimulation for primary cervical dystonia: one year follow up results of a prospective multicenter trial. Parkinsonism Relat Disord 2015;21(8):976-80. PMID 26074391
47: Dressler D, Pan L, Saberi FA. Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity. J Neural Trans 2018;125:1481-6. PMID 30066275
48: Erro R, Rocchi L, Antelmi E, et al. High frequency somatosensory stimulation in dystonia: evidence for defective inhibitory plasticity. Mov Disord 2018;33:1902-9. PMID 30376603
49: Ertekin C, Aydogdu I, Secil Y, Kiylioglu N, Tarlaci S, Ozdemirkiran T. Oropharyngeal swallowing in craniocervical dystonia. J Neurol Neurosurg Psychiatry 2002;73(4):406-11. PMID 12235309
50: Evidente VG, Truong D, Jankovic J, Comella CL, Grafe S, Hanschmann A. IncobotulinumtoxinA (Xeomin(R)) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci 2014;346(1-2):116-20. PMID 25186131
51: Ferrazzano G, Belvisi D, De Bartolo MI, et al. Longitudinal evaluation of patients with isolated head tremor. Parkinsonism Relat Disord 2022;94:10-2. PMID 34861560
52: Finsterer J, Maeztu C, Revuelta GJ, Reichel G, Truong D. Collum-caput (COL-CAP) concept for conceptual anterocollis, anterocaput, and forward sagittal shift. J Neurol Sci 2015;355(1-2):37-43. PMID 26088286
53: Foltz EL, Knopp LM, Ward AA. Experimental spasmodic torticollis. J Neurosurg 1959;16:55-67. PMID 13621265
54: Fox SH, Swan M, Jinnah H, et al. An open-label phase 2a study to evaluate the safety and tolerability of perampanel in cervical dystonia. Mov Disord Clin Pract 2021;8(5):743-9. PMID 34307747
55: Fuchs T, Saunders-Pullman R, Masuho I, et al. Mutations in GNAL cause primary torsion dystonia. Nat Genet 2012;45;88-92. PMID 23222958
56: Godeiro-Junior C, Felicio AC, Aguiar PC, Borges V, Silva SM, Ferraz HB. Neuroleptic-induced tardive cervical dystonia: clinical series of 20 patients. Can J Neurol Sci 2009;36(2):222-6. PMID 19378719
57: Goldman S, Ahlskog JE. Posttraumatic cervical dystonia. Mayo Clin Proc 1993;68(5):443-8. PMID 8479207
58: Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 1998;50(6):1624-9. PMID 9633703
59: Huh R, Chung M. Range of voluntary neck motility predicts outcome of pallidal DBS for cervical dystonia. Acta Neurochir (Wien) 2019;161(12):2491-8. PMID 31659440
60: Ikeda K, Yanagihashi M, Sawada M, Hanashiro S, Kawabe K, Iwasaki Y. Donepezil-induced cervical dystonia in Alzheimer's disease: a case report and literature review of dystonia due to cholinesterase inhibitors. Intern Med 2014;53(9):1007-10. PMID 24785894
61: Jahanshahi M, Marion MH, Marsden CD. Natural history of adult-onset idiopathic torticollis. Arch Neurol 1990;47(5):548-52. PMID 2334302
62: Jankovic J. Botulinum toxin: State of the art. Mov Disord 2017a;32(8):1131-8. PMID 28639368
63: Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon 2017b;147:84-8. PMID 28888928
64: Jankovic J, Adler CH, Charles D, et al. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci 2015;349(1-2):84-93. PMID 25595221
65: Jankovic J, Truong D, Patel AT, et al. Injectable daxibotulinumtoxinA in cervical dystonia: a phase 2 dose-escalation multicenter study. Mov Disord Clin Prac 2018;5:273-82. PMID 30009213
66: Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord 2007;13(7):411-6. PMID 17442609
67: Jinnah HA, Goodmann E, Rosen AR, Evatt M, Freeman A, Factor S. Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. J Neurol 2016;263(6):1188-94.** PMID 27113604
68: Jinnah HA, Neychev V, Hess EJ. The anatomical basis for dystonia: the motor network model. Tremor Other Hyperkinet Mov (N Y) 2017;7:506.** PMID 29123945
69: Jost, WH, Tatu L, Pandey S, et al. Frequency of different subtypes of cervical dystonia: a prospective multicenter study according to Col-Cap concept. J Neural Trans 2020;127(1):45-50. PMID 31828512
70: Khanom AA, Franceschini PR, Lane S, et al. Bilateral globus pallidus internus (GPI) deep brain stimulation for cervical dystonia: Effects on motor and non-motor symptoms within 5 years follow. J Neurological Sci 2023;452:120752. PMID 37542824
71: Kilic-Berkmen G, Pirio Richardson S, Perlmutter JS, et al. Current guidelines for classifying and diagnosing cervical dystonia: empirical evidence and recommendations. Mov Disord 2021;9(2):183-90. PMID 35146058
72: Koch G, Porcacchia P, Ponzo V, et al. Effects of two weeks of cerebellar theta burst stimulation in cervical dystonia patients. Brain Stimul 2014;7(4):564-72. PMID 24881805
73: Koukouni V, Martino D, Arabia G, Quinn NP, Bhatia KP. The entity of young onset primary cervical dystonia. Mov Disord 2007;22(6):843-7. PMID 17357144
74: Kumar KR, Lohmann K, Masuho I, et al. Mutations in GNAL: a novel cause of craniocervical dystonia. JAMA Neurol 2014;71(4):490-4. PMID 24535567
75: LeDoux MS, Brady KA. Secondary cervical dystonia associated with structural lesions of the central nervous system. Mov Disord 2003;18(1):60-9. PMID 12518301
76: LeDoux MS, Vemula SR, Xiao J, et al. Clinical and genetic features of cervical dystonia in a large multicenter cohort. Neurol Genet 2016;2(3):e69. PMID 27123488
77: Leube B, Hendgen T, Kessler KR, Knapp M, Benecke R, Auburger G. Evidence for DYT7 being a common cause of cervical dystonia (torticollis) in Central Europe. Am J Med Genet 1997;74(5):529-32. PMID 9342206
78: Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49(3):701-7. PMID 9305326
79: Li Z, Prudente CN, Stilla R, Sathian K, Jinnah HA, Hu X. Alterations of resting-state fMRI measurements in individuals with cervical dystonia. Hum Brain Mapp 2017;38(8):4098-108. PMID 28504361
80: Liu C, Scorr L, Kilic-Berkmen G, et al. A metabolomic study of cervical dystonia. Parkinsonism Relat Disord 2021;82:98-103. PMID 33271463
81: Lizarraga KJ, Al-Shorafat D, Fox S. Update on current and emerging therapies for dystonia. Neurodegener Dis Manag 2019;9(3):135-47. PMID 31117876
82: Loh A, Elias GJ, Germann J, et al. Neural correlates of optimal deep brain stimulation for cervical dystonia. Ann Neurol 2022;92(3):418-24. PMID 35785489
83: Louis ED, Hernandez N, Alcalay RN, Tirri DJ, Ottman R, Clark LN. Prevalence and features of unreported dystonia in a family study of "pure" essential tremor. Parkinsonism Relat Disord 2013;19(3):359-62. PMID 23089243
84: Ma L, Chen R, Wang L, Yang Y, Wan X. No mutations in CIZ1 in twelve adult-onset primary cervical dystonia families. Mov Disord 2013;28(13):1899-901. PMID 23813719
85: Mahajan A, Jankovic J, Marsh L, et al. Cervical dystonia and substance abuse. J Neurol 2018;265:970-5. PMID 29569175
86: Mahajan A, Schroder L, Rekhtman A, et al. Tremor-dominant cervical dystonia: a cerebellar syndrome. Cerebellum 2021;20(2):300-5. PMID 33161481
87: Mahlknecht P, Georgiev D, Akram H, et al. Parkinsonian signs in patients with cervical dystonia treated with pallidal deep brain stimulation. Brain 2018;141:3023-34. PMID 30165511
88: Marion MH, Hicklin LA. Botulinum toxin treatment of dystonic anterocollis: what to inject. Parkinsonism Relat Disord 2021;88:34-9. PMID 34102419
89: Mente K, Edwards NA, Urbano D, et al. Pedunculopontine nucleus cholinergic deficiency in cervical dystonia. Mov Disord 2018;33:827-33. PMID 29508906
90: Molho ES, Feustel PJ, Factor SA. Clinical comparison of tardive and idiopathic cervical dystonia. Mov Disord 1998;13:486-9. PMID 9613742
91: Molho ES, Stacy M, Gillard P, et al. Impact of cervical dystonia on work productivity: and analysis from a patient registry. Mov Disord Clin Prac 2016:3:130-8. PMID 27774495
92: Moriarty A, Rafee S, Ndukwe I, et al. Longitudinal follow‐up of mood in cervical dystonia and influence on age at onset. Mov Disord Clin Prac 2022;9(5):614-8. PMID 35844277
93: Muller J, Wenning GK, Wissel J, et al. Riluzole therapy in cervical dystonia. Mov Disord 2002;17(1):198-200. PMID 11835465
94: Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA across multiple indications. Mov Disord 2010;25:2211-8. PMID 20737546
95: Neumann WJ, Horn A, Ewert S, et al. A localized pallidal physiomarker in cervical dystonia. Ann Neurol 2017;82:912-24. PMID 29130551
96: Newby RE, Thorpe DE, Kempster PA, Alty JE. A history of dystonia: ancient to modern. Mov Disord Clin Pract 2017;4(4):478-85. PMID 28920067
97: Norris SA, Jinnah HA, Espay AJ, et al. Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Mov Disord 2016;31(12):1874-82. PMID 27753188
98: O’Riordan S, Hutchinson M. Cervical dystonia following peripheral trauma – a case-control study. J Neurol 2004;251(2):150-5. PMID 14991348
99: Ostrem JL, Racine CA, Glass GA, et al. Subthalamic nucleus deep brain stimulation in primary cervical dystonia. Neurology 2011;76(10):870-8. PMID 21383323
100: Ozturk O, Gunduz A, Kiziltan M. Cortical modulation of brainstem circuits is abnormal in cervical dystonia. Neurosci Let 2018;677:84-7. PMID 29704573
101: Patel N, Hanfelt J, Marsh L, Jankovic J, members of the Dystonia Coalition. Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry 2014a;85(8):882-4. PMID 24828895
102: Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol 2014b;13(1):100-12. PMID 24331796
103: Pirio Richardson S, Wegele AR, Skipper B, et al. Dystonia treatment: patterns of medication use in an international cohort. Neurology 2017;88(6):543-50. PMID 28077492
104: Prudente CN, Pardo CA, Xiao J, et al. Neuropathology of cervical dystonia. Exp Neurol 2013;241:95-104. PMID 23195594
105: Ramirez-Castaneda J, Jankovic J. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon 2014;90:344-8.** PMID 25130293
106: Richter A, Hollstein R, Hebert E, et al. In-depth characterization of the homodimerization domain of the transcription factor THAP1 and dystonia-causing mutations therein. J Mol Neurosci 2017;62(1):11-6. PMID 28299530
107: Riski JE, Horner J, Nashold BS Jr. Swallowing function in patients with spasmodic torticollis. Neurology 1990;40(9):1443-5. PMID 2392232
108: Sa DS, Malis-Gagnon A, Nicholson K, Lang AE. Posttraumatic painful torticollis. Mov Disord 2003;18(12):1482-91. PMID 14673885
109: Sako W, Murakami N, Izumi Y, Kaji R. Val66Met polymorphism of brain-derived neurotrophic factor is associated with idiopathic dystonia. J Clin Neurosci 2015;22(3):575-7. PMID 25523127
110: Samii A, Pal PK, Schulzer M, Mak E, Tsui JK. Post-traumatic cervical dystonia: a distinct entity. Can J Neurol Sci 2000;27(1):55-9. PMID 10676589
111: Samotus O, Lee J, Jog M. Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance. J Neurol 2018;265:1269-78. PMID 29557988
112: Schiebler S, Schmidt A, Zittel S, et al. Arm tremor in cervical dystonia--is it a manifestation of dystonia or essential tremor? Mov Disord 2011;26(10):1789-92. PMID 21735481
113: Schneider SA, Mohire MD, Trender-Gerhard I, et al. Familial dopa-responsive cervical dystonia. Neurology 2006;66(4):599-601. PMID 16505323
114: Shaikh AG, Zee DS, Jinnah HA. Oscillatory head movements in cervical dystonia: Dystonia, tremor, or both? Mov Disord 2015;30(6):834-42. PMID 25879911
115: Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016;86(19):1818-26.** PMID 27164716
116: Sondergaard RE, Rockel CP, Cortese F, et al. Microstructural abnormalities of the dentatorubrothalamic tract in cervical dystonia. Mov Disord 2021;36(9):2192-8. PMID 34050556
117: Stamelou M, Charlesworth G, Cordivari C, et al. The phenotypic spectrum of DYT24 due to ANO3 mutations. Mov Disord 2014;29(7):928-34. PMID 24442708
118: Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord 2012;27(14):1789-96. PMID 23114997
119: Stemp LI, Taswell C. Spastic torticollis during general anesthesia: case report and review of receptor mechanisms. Anesthesiology 1991;75(2):365-6. PMID 1677550
120: Suchowersky O, Calne DB. Non-dystonic causes of torticollis. In: Fahn S, Marsden CD, Calne DB, editors. Dystonia 2. New York: Raven, 1988;50:501-8.
121: Sun YV, Li C, Hui Q, et al. A multi-center genome-wide association study of cervical dystonia. Mov Disord 2021;36(12):2795-801. PMID 34320236
122: Tewari A, Fremont R, Khodakhah K. It's not just the basal ganglia: Cerebellum as a target for dystonia therapeutics. Mov Disord 2017;32(11):1537-45. PMID 28843013
123: Tiderington E, Goodman EM, Rosen AR, et al. How long does it take to diagnose cervical dystonia. J Neurol Sci 2013;335(1-2):72-4. PMID 24034410
124: Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005;20(7):783-91. PMID 15736159
125: Truong DD, Dubinsky R, Hermanowicz N, Olson WL, Silverman B, Koller WC. Posttraumatic torticollis. Arch Neurol 1991;48(2):221-3. PMID 1993013
126: Valente EM, Bentivoglio AR, Cassetta E, et al. Identification of a novel primary torsion dystonia locus (DYT13) on chromosome 1p36 in an Italian family with cranial-cervical or upper limb onset. Neurol Sci 2001;22(1):95-96. PMID 11487218
127: van den Dool J, Tijssen MA, Koelman JH, Engelbert RH, Visser B. Determinants of disability in cervical dystonia. Parkinsonism Relat Disord 2016;32:48-53. PMID 27553512
128: Volkmann J, Mueller J, Deuschl G, et al. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol 2014;13(9):875-84.** PMID 25127231
129: Walsh RA, Sidiropoulos C, Lozano AM, et al. Bilateral pallidal stimulation in cervical dystonia: blinded evidence of benefit beyond 5 years. Brain 2013;136(Pt 3):761-9. PMID 23423670
130: Williams L, McGovern E, Kimmich O, et al. Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland. Eur J Neurol 2017;24(1):73-81. PMID 27647704
131: Winter P, Kamm C, Biskup S, et al. DYT7 gene locus for cervical dystonia on chromosome 18p is questionable. Mov Disord 2012;27(14):1819-21. PMID 23115116
132: Witt JL, Moro E, Ash RS, et al. Predictive factors of outcome in primary cervical dystonia following pallidal deep brain stimulation. Mov Disord 2013;28(10):1451-5. PMID 23787946
133: Wu R, Dou W, Zhou H, et al. A novel compound heterozygous mutation of COL6A3 in Chinese patients with isolated cervical dystonia. Front Neurol 2023;14. PMID 37082441
134: Xiao J, Uitti RJ, Zhao Y, et al. Mutations in CIZ1 cause adult onset primary cervical dystonia. Ann Neurol 2012;71(4):458-69. PMID 22447717
135: Zhang J, Weinrich JAP, Russ JB, et al. A role for dystonia-associated genes in spinal GABAergic interneuron circuitry. Cell Rep 2017;21(3):666-78. PMID 29045835
136: Zheng Z, Pan P, Wang W, Shang H. Neural network of primary focal dystonia by an anatomic likelihood estimation meta-analysis of gray matter abnormalities. J Neurol Sci 2012;316(1-2):51-5. PMID 22349356

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Eric Steven Molho MD

Dr. Molho of Albany Medical College has received honoraria as a speaker for Neurocrine Biosciences; fees as a consultant for UCB Pharma and Supernus Pharmaceuticals; educational grants from Merz North America, AbbVie Inc., and Allergan; and research grant support from Amneal Pharmaceuticals, Biohaven, Enterin Inc., and Cerevel Therapeutics.
See Profile
Gary Volkell DO

Dr. Volkell of MedStar Franklin Square Medical Center received a consulting fee from Supernus Pharmaceuticals.
See Profile

Editor

Robert Fekete MD

Dr. Fekete of New York Medical College received consultation fees from Acadia Pharmaceutical, Acorda, Adamas/Supernus Pharmaceuticals, Amneal/Impax, Kyowa Kirin, Lundbeck Inc., Neurocrine Inc., and Teva Pharmaceutical, Inc.
See Profile

Former Authors

Joseph K C Tsui MD
Mary Ann Thenganatt MD
Kristopher Grajny MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: female>male
Heredity: Heredity may be a factor
Population groups selectively affected: none
Occupation groups selectively affected: none

ICD & OMIM codes

ICD-10: Spasmodic torticollis: G24.3
ICD-11: Other specified primary dystonia: 8A02.0Y
OMIM: DYT 25 (GNAL): 615073

DYT23 (CIZ1): 611420

DYT6 (THAP1): 602629

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Cervical dystonia

Associated Disorders

Blepharospasm
Laryngeal dystonia
Limb dystonia
Oromandibular dystonia
Tremor

Differential Diagnosis

essential tremor
secondary causes of torticollis
drug-induced cervical dystonia
congenital abnormalities
traumatic brain abnormalities
- septic arthritis
- cervical epidural abscess
- osteomyelitis
- cerebellar cavernous angioma
- posterior fossa tumor
- spinal astrocytoma
- spinal ependymoma
- Sandifer syndrome
- congenital shortening
- fibrosis of the sternocleidomastoid muscle
- congenital vertebral anomalies
- trochlear nerve palsy
- ocular muscle palsies
- vestibular diseases
- basal ganglia infarction
- psoriatic spondylitis
- midbrain lesions in multiple sclerosis
- ataxia-telangiectasia
- psychogenic cervical dystonia

Also Relevant

Basal ganglia: functional anatomy and neuropharmacology
Blepharospasm
Botulinum toxin treatment of neurologic disorders
Idiopathic torsion dystonia
Peripheral dystonia
- Rating scales of movement disorders
- Tardive dystonia

Clinical Categories

Movement Disorders

Patient Handouts

Web References

Alerts and Advisories

FDA approves DAXXIFY® (daxibotulinumtoxinA-lanm) for cervical dystonia

Cervical dystonia …

Cervical dystonia

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

Cervical dystonia

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

This is an article preview.
Start a Free Account
to access the full version.